Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Lectins » Anti -Galectin-1 (GAL1, LGALS1, GAL-1, Lectin galactoside-binding soluble 1, Beta-galactoside- binding lectin L-14-I, Lactose-binding lectin 1, S-Lac lectin 1, Galaptin, 14kD lectin, HPL, HBL, Putative MAPK-activating protein PM12, GBP, DKFZp686E23103)

Anti -Galectin-1 (GAL1, LGALS1, GAL-1, Lectin galactoside-binding soluble 1,
Beta-galactoside- binding lectin L-14-I, Lactose-binding lectin 1, S-Lac lectin 1,
Galaptin, 14kD lectin, HPL, HBL, Putative MAPK-activating protein PM12, GBP,
DKFZp686E23103)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Polyclonal Rabbit Affinity Purified E B
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Galectin-1 is an autocrine negative growth factor that regulates cell proliferation. Galectin-1 regulates cell apoptosis and cell differentiation. Galectin-1 binds CD45, CD3 and CD4 & inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of lyn kinase. Galectin-1 and its ligands are one of the master regulators of immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host–pathogen interactions. Galectin-1 expression or overexpression in tumors and/or the tissue surrounding them must be considered as a sign of the malignant tumor progression that is often related to the long-range dissemination of tumoral cells (metastasis), to their dissemination into the surrounding normal tissue, and to tumor immune-escape. Galectin-1 in its oxidized form plays a number of important roles in the regeneration of the central nervous system after injury. The targeted overexpression (or delivery) of Galectin-1 should be considered as a method of choice for the treatment of some kinds of inflammation-related diseases, neurodegenerative pathologies and muscular dystrophies. In contrast, the targeted inhibition of Galectin-1 expression is what should be developed for therapeutic applications against cancer progression. Galectin-1 is thus a promising molecular target for the development of new and original therapeutic tools.
Catalog #G1044-47
ApplicationsSuitable for use in ELISA and Western Blot. Other applications not tested.
Recommended DilutionELISA (Indirect, Sandwich): 0.5-2ug/ml. Using 100ul/well antibody solution. In conjunction with compatible secondary reagents, allows a detection of 0.2-0.4ng/well of recombinant hGalectin-1.
Western Blot: 0.1-0.2ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hGalectin-1 is 1.5-3.0ng/lane, under either reducing or non-reducing conditions.
Optimal dilutions to be determined by the researcher.
Storage and StabilityLyophilized powder may be stored at -20°C. Reconstitute to nominal volume by adding sterile 40-50% glycerol, ddH2O. Aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clone TypePolyclonal
IsotypeIgG
HostRabbit
SourceHuman
Concentration~1mg/ml
FormSupplied as a lyophilized powder from PBS, pH 7.2. Reconstitute with sterile 40-50% glycerol, ddH2O to a concentration of 0.1-1mg/ml.
PurityPurified by immunoaffinity chromatography.
ImmunogenHighly pure (>98%) recombinant human Galectin-1.
SpecificityRecognizes human Galectin-1.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links